JPRN-jRCT2080220994未知3 期
A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)
Ajinomoto Pharmaceuticals Co., Ltd.0 个研究点开始时间: 2010年2月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •[Main inclusion criteria]
- •-Aged 50 years or older at the time of obtaining consent
- •-Female subjects must be at least 2 years postmenopausal (i.e., at least 2 years since last menstrual period)
排除标准
- •[Main exclusion criteria]
- •-Secondary osteoporosis
- •-Presence of any disease that can decrease bone mass, except secondary osteoporosis
- •-Findings that can affect DXA measurements of mean lumbar spine bone mineral density
- •-Prior radiotherapy to the lumbar spine or pelvic region
- •-Planned dental extraction or other dental surgical procedures (including dental implants) to be
- •performed during the study period
研究者
相似试验
未知
3 期
A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)JPRN-jRCT2080220992Takeda Pharmaceutical Company Limited
未知
2 期
PhaseII/III double-blind comparative study of the efficacy and safety of TAK-536CCB when coadministered with hydrochlorothiazide in patients with grade I or II essential hypertensioHypertensionJPRN-jRCT2080221917TAKEDA PHARMACEUTICAL COMPANY LTD.
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed by Nivolumab or Placebo provided after surgery for Participants with Non-small Cell Lung Cancer which can be completely removed by surgery.Resectable Stage II-IIIB Non-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000262-38-ITBristol-Myers Squibb International Corporation750
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed by Nivolumab or Placebo provided after surgery for Participants with Non-small Cell Lung Cancer which can be completely removed by surgery.Resectable Stage II-IIIB Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000262-38-NLBristol-Myers Squibb International Corporation750
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed by Nivolumab or Placebo provided after surgery for Participants with Non-small Cell Lung Cancer which can be completely removed by surgery.EUCTR2019-000262-38-ROBristol-Myers Squibb International Corporation750